SISCAPA and Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions

Article content

Empowering biopharma with seamless, high-precision workflows from biomarker discovery to targeted enrichment and protein quantification for clinical trials

Article content

Article content

WASHINGTON and ZURICH, May 19, 2025 (GLOBE NEWSWIRE) — SISCAPA Assay Technologies, a global leader in high-sensitivity protein quantitation, and Biognosys, a pioneer in next-generation proteomics, today announced an exclusive strategic collaboration to offer biopharma customers a streamlined end-to-end solution for high-sensitivity protein analysis—from early protein biomarker and drug target discovery, all the way to targeted enrichment and protein quantification in preclinical studies and clinical trials application. This collaboration strengthens Biognosys’ clinical biomarker monitoring and targeted proteomics service offering, enabling the company to support its global biopharma customers with translational and validated assays for clinical trials.

Article content

Article content

Biognosys’ TrueDiscovery platform delivers deep, unbiased proteomic insights across a wide range of tissues and biological fluids, enabling customers to uncover novel biomarkers with confidence. These discoveries can be seamlessly translated into targeted assays under Biognosys’ TrueSignature platform, which is supported by robust operational capabilities and has already been deployed successfully in preclinical research and clinical trial settings with multiple biopharma partners.

Article content

Article content

SISCAPA’s technology uses highly specific antibodies coupled with mass spectrometry to enrich and quantify target peptides, achieving unprecedented sensitivity, specificity, and reproducibility, even in the most complex biological samples.

Article content

Under this partnership, Biognosys becomes the preferred service provider for delivering SISCAPA’s groundbreaking immuno-enrichment technology to biopharma customers. This collaboration significantly enhances Biognosys’ capabilities, enabling high-sensitivity, high-accuracy, and scalable protein analysis for clinical biomarker monitoring.

Article content

Article content

Biopharma customers can now benefit from:

Article content

Article content

“SISCAPA is extremely pleased to be working with the superb Biognosys team to simplify access to the transformational power of protein mass spectrometry from discovery, through drug development, and all the way to clinical biomarker monitoring. By directly connecting our technologies, we can provide a seamless roadmap for understanding protein biomarkers, targets and drugs,” said Leigh Anderson, Ph.D., CEO and Founder of SISCAPA Assay Technologies.

Article content

“At Biognosys, we are committed to empowering our biopharma partners with the most advanced and robust proteomics solutions, from discovery to clinical application. This collaboration with SISCAPA brings together two world-class teams to create a truly end-to-end workflow for high-sensitivity protein quantification. By integrating our strengths, we are enabling customers to accelerate biomarker development and confidently translate their discoveries into impactful clinical insights,” said Oliver Rinner, Ph.D., CEO and Co-Founder of Biognosys.